These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 30586344)

  • 41. Vismodegib in the treatment of advanced BCC.
    O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
    Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report.
    Awad R; Andrade JCB; Mousa H; Mahmoud F
    Perm J; 2018; 22():17-181. PubMed ID: 30005721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
    Dubey AK; Dubey S; Handu SS; Qazi MA
    J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
    Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
    Keserü M; Green S; Dulz S
    Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
    Bayers S; Kapp DL; Beer KR; Slavin B
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
    Yin VT; Esmaeli B
    Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
    Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
    Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
    Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
    Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
    Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
    JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
    Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
    Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current landscape for treatment of advanced basal cell carcinoma.
    Foley P
    Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
    Alfieri S; Romanò R; Marceglia S; De Giorgi V; Peris K; Sollena P; Piccerillo A; Moro R; Gualdi G; Ascierto PA; Palla M; Paone M; Eibenschutz L; Spagnolo F; Queirolo P; Filippini DM; Cavalieri S; Resteghini C; Bergamini C; Manocchio A; Licitra L; Bossi P
    Oncologist; 2024 May; 29(5):e699-e707. PubMed ID: 38127280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib.
    Smith SDB; Clarke CN; Clark MA; Harker-Murray AK; Sokumbi O
    Am J Dermatopathol; 2021 Aug; 43(8):585-587. PubMed ID: 33534208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
    Sand M; Bechara FG; Gambichler T; Sand D; Friedländer MR; Bromba M; Schnabel R; Hessam S
    Ann Oncol; 2016 Feb; 27(2):332-8. PubMed ID: 26578727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.